A notable example is galanthamine (also known as galantamine), an FDA-approved drug marketed under the brand names ReminylTM (Janssen Research Foundation, Beerse, Belgium, 2001) and RazadyneTM (Johnson & Johnson Pharmaceutical Research, New Brunswick, NJ, USA, 2004) for the treatment of mild to moderate Alzheimer’s disease, due to its potent acetylcholinesterase-inhibitory activity. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.